Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis

Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis


Lead sponsor: Keesler Air Force Base Medical Center

Source Keesler Air Force Base Medical Center
Brief Summary

To date no trials have been performed looking at whether or not intra-bursal injection of an IL-1 antagonist provides pain relief similar to that of a corticosteroid injection. The subcutaneous injection of anakinra, an IL-1 receptor antagonist, in patients with shoulder pain due to rotator cuff tendonitis and subacromial bursitis was efficacious in relieving pain but this information was presented as a case series in a letter to the editor format, so the validity of these results would require additional testing [Omoigui S, et al. 2004]. Based mainly on the data from the intra-articular administration of anakinra, there have not been any adverse trends in outcomes or safety to suggest that intra-bursal injection of rilonacept will carry an increase risk of adverse events. The purpose of this trial is to compare the improvement in pain and function of patients with clinical symptoms and signs of subacromial bursitis of rilonacept vs. corticosteroid injection (standard of care).

Detailed Description

Background: Subacromial bursitis is an inflammatory condition which is typically triggered by altered rotator cuff mechanics. One of the mainstays of therapy is corticosteroid injection. Given the inflammatory nature of subacromial bursitis coupled with prominence of interleukin-1 (IL-1) beta on histopathologic assessment of resected subacromial bursa, targeted anti-IL-1 therapy would be an attractive alternative to corticosteroid injection.

Hypothesis: One intra-bursal injection of the IL-1 trap rilonacept (Arcalyst ®), currently FDA approved for the treatment of cryopyrin associated periodic syndrome (CAPS), is non-inferior to intra-bursal corticosteroid injection at 4 weeks post-procedure.

Methods: This study is a prospective trial lasting a total of 4 weeks. Patients with typical symptoms and signs of subacromial bursitis are randomized to either corticosteroid injection prepared in the usual fashion in clinic vs. injection of rilonacept. Prior to injection of either medication patients will complete a QuickDASH Questionnaire and provide a verbal pain score from 0 to 10. The Quick DASH Questionnaire and verbal pain score are then completed within 2 duty days of injection, 2 weeks after injection, and 4 weeks after injection by phone.

Primary Outcome: Primary outcome is improvement in QuickDASH. Secondary outcomes are improvement in the verbal pain score and monitoring for infection or other complications from rilonacept administration.

Overall Status Completed
Start Date March 2013
Completion Date March 2014
Primary Completion Date March 2014
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
Improvement in Shoulder Function 4 weeks
Secondary Outcome
Measure Time Frame
Improvement in Pain 4 weeks
Number of Participants With Adverse Events as a Measure of Safety and Tolerability 4 weeks
Enrollment 33

Intervention type: Drug

Intervention name: Rilonacept

Description: 160 mg intra-bursal once

Arm group label: Rilonacept

Other name: Arcalyst

Intervention type: Drug

Intervention name: Corticosteroid

Description: 2 cc (40 mg/mL) triamcinolone intra-bursal once

Arm group label: Corticosteroid

Other name: Triamcinolone (Kenalog)



Inclusion Criteria:

- At least 18 years of age or older and at a minimum have a recent history (more than 3 days worth) of shoulder pain with moderate to severe tenderness to palpation over the subacromial bursa.

Exclusion Criteria:

- Allergies to lidocaine, marcaine, or kenalog.

- Allergies to rilonacept

- Flare of active inflammatory arthritis (such as a flare of Rheumatoid Arthritis)

- Gout or Pseudogout attack of the shoulder with subacromial tenderness

- Active infection

- Actively receiving chemotherapy, radiation therapy, or anticipating surgery for neoplasia

- Active myocardial infarction

- Clinical and/or radiographic evidence of a fracture (clavicular, humeral, or other).

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Overall Official
Last Name Role Affiliation
Matthew B Carroll, MD Principal Investigator Keesler Medical Center
facility Keesler Medical Center
Location Countries

United States

Verification Date

July 2014

Responsible Party

Responsible party type: Sponsor

Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Arm group label: Rilonacept

Arm group type: Active Comparator

Description: 160 mg of rilonacept will be injected in the subacromial bursa of participants in this arm.

Arm group label: Corticosteroid

Arm group type: Placebo Comparator

Description: 80 mg (2 cc of 40 mg/mL) Kenalog intra-bursal once

Study Design Info

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Treatment

Masking: None (Open Label)